Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Regeneron Pharmaceuticals Inc

+ Add to Watchlist


413.840 USD 6.030 1.44%

As of 17:20:00 ET on 02/27/2015.

Snapshot for Regeneron Pharmaceuticals Inc (REGN)

Open: 421.040 Day's Range: 411.043 - 421.070 Volume: 811,005
Previous Close: 419.870 52wk Range: 269.500 - 437.638 1-Yr Rtn: +24.46%

Stock Chart for REGN

No chart data available.
  • REGN:US 413.840
  • 1D
  • 1M
  • 1Y
Interactive REGN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for REGN

Current P/E Ratio (ttm) 127.2930
Estimated P/E(12/2015) 38.7346
Relative P/E vs. SPX 7.2464
Earnings Per Share (USD) (ttm) 3.2511
Est. EPS (USD) (12/2015) 10.6840
Est. PEG Ratio 2.0754
Market Cap (M USD) 42,467.00
Shares Outstanding (M) 100.65
30 Day Average Volume 813,671
Price/Book (mrq) 16.6737
Price/Sale (ttm) 14.7389
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for REGN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for REGN

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

Leonard S Schleifer "Len"President/CEO/Co-FounderGeorge D YancopoulosPres:Laboratories
Joseph J Larosa "Joe"Senior VP/Secy/General CounselDaniel P Van PlewSenior VP/Gen Mgr:Industrial Ops
More Company Profile & Key Executives for REGN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil